Using N-acetylcysteine with Oseltamivir for Severe Influenza in Hospitalized Adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of intravenous N-acetylcysteine (NAC) combined with oseltamivir in adults hospitalized with severe influenza and pneumonia. The study aims to evaluate whether NAC, known for its antioxidant properties, can improve clinical outcomes by reducing inflammation in patients suffering from lower respiratory tract infections. Participants will be randomly assigned to receive either the combination treatment or oseltamivir alone, with outcomes assessed based on respiratory status and overall health improvements. The trial is designed to provide insights into the potential benefits of adjunctive NAC therapy in managing severe influenza cases.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* influenza A and B virus infections confirmed by polymerase chain reaction (PCR) and/or immunofluorescence assays,
* hospitalized for the management of severe manifestations of influenza,
* initiation of oseltamivir,
* clinical evidence of lower respiratory tract infection (e.g. shortness of breath, tachypnea, oxygen desaturation \<93% on room air, crepitations on auscultation, infiltrations or consolidations on chest radiograph)
* written informed consent (by the subjects, or from their next of kin if the subjects are unable to provide written consent at the time of enrollment)

Exclusion Criteria:

* use of immunosuppressants (e.g. post-chemotherapy, post-transplant, autoimmune diseases) other than systemic corticosteroids
* known immuno-compromised conditions (e.g. active haematological malignancies, HIV/AIDS patients who are on antiretroviral therapy and CD4 cell count \< 200),
* pregnancy
* lactation,
* end-stage renal failure
* hepatic failure
* cardiac failure
* patients on anticoagulation (except prophylactic dose of low molecular weight heparin),
* patients with scheduled major surgery within 2 weeks (NAC may affect blood clotting),
* patients who have received macrolide antibiotics and NSAID for 1 week prior to enrolment due to their immuno-modulating effects.
* Use of investigational anti-influenza antivirals and blood products

Where it's running

• Prince of Wales Hospital
  Hong Kong, Hong Kong Recruiting

Study contacts

• Principal investigator: David SC Hui, MD — Chinese University of Hong Kong
• Study coordinator: Ken Ka Pang Chan, MBChB
• Email: chankapang@cuhk.edu.hk
• Phone: 852 3505 3532

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-dose vs standard-dose flu vaccine in adults with blood cancers on B-cell-depleting therapy

  This study tests whether a high-dose flu shot evokes a stronger immune response than a standard-dose shot in adults with hematologic cancers who recently had B-cell-depleting therapy.

  Recruiting Phase 2 Asan Medical Center · Seoul · NCT07926217

• Abbott ID NOW at the point of care for flu-like illness in long-term care facilities

  This trial tests whether the Abbott ID NOW rapid test at the point of care in long-term care facilities can help identify influenza sooner for residents 65 and older with fever and respiratory symptoms.

  Recruiting China Medical University Hospital · Taichung · NCT07846423

• Egg-based H5N8 influenza vaccine at multiple doses with or without adjuvant in healthy adults

  This trial tests whether an egg-based H5N8 flu vaccine, given at low to high doses with or without an adjuvant, is safe and can provoke a stronger immune response in healthy adults 18 and older.

  Recruiting at 16 sites Phase 1/2 Sanofi · Tempe, Arizona and 15 other locations · NCT07779408

• Safety and PK of Ingavirin Forte vs Ingavirin in healthy adults under fasting and fed conditions

  This early-phase study tests whether Ingavirin Forte (90 mg + 20 mg) is safe and how it behaves in the body compared with Ingavirin (90 mg) in healthy adults aged 18–45, under different meal conditions.

  Recruiting Phase 1 Valenta Pharm JSC · Saint Petersburg · NCT07645534

• Light-based immune boost to help prevent viral upper respiratory infections

  A daily handheld light therapy device is tested to see if it can lower how often adults at a military medical facility get colds, flu, or other upper respiratory infections.

  Recruiting Mike O'Callaghan Military Hospital · Nellis Air Force Base, Nevada · NCT07610967

• Virological Monitoring of Seasonal Respiratory Infections in France

  This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Paris · NCT07599449

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.